Gem Aromatics Ltd
Gem Aromatics Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #33 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
GEM Aromatics is focused on scaling high-value specialty products and improving utilization levels, especially at the Dahej facility. FY ‘27 guidance is cautious due to geopolitical uncertainties and raw material price volatility; detailed guidance expected in 1-2 quarters.
From Gem Aromatics Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- GEM Aromatics is focused on scaling high-value specialty products and improving utilization levels, especially at the Dahej facility.
- The company expects FY ‘27 to perform closer to FY ‘25 levels, with better business momentum compared to FY ‘26 affected by geopolitical issues.
- New capacity at Dahej has potential revenue of ~INR800 crores with gradual ramp-up planned, though full utilization guidance is expected by H2 FY ‘27.
- The company is witnessing positive order flows and improving customer engagement, signaling recovery and growth.
- Operating leverage benefits and product mix optimization are expected to support margin and profitability expansion.
2 more points from Gem Aromatics Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Gem Aromatics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total planned capex for Dahej project is approximately INR 270 crores, with nearly INR 260 crores already incurred and substantially capitalized (Page 4).
- The Dahej facility has commenced commercial production (Gemcool 5, Safranal) and is positioned for ramp-up during FY ‘27, with asset turnover expected around 3 to 3.5 times and peak revenue potential of about INR 800 crores (Pages 4, 5).
- Further investments are focused on scaling high-value specialty products and strengthening global manufacturing capabilities, including multipurpose capacity for CRO, CMO, and CDMO services at Dahej (Pages 13, 15).
2 more points from Gem Aromatics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gem Aromatics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company indicated improving business momentum with strong order and deal flows coming through, particularly after the Q4 FY26 dip.
- Product qualification with distributors/traders globally is complete for new phenol-based products; distributors are ready to order once raw material prices stabilize.
- There is a positive outlook on scaling up orders as tariffs issues ease and exports resume, especially to the U.S. market.
- The Dahej facility has just gone live (April 2026), with ramp-up expected through FY27; exact utilization and order backlog figures will be clearer by H2 FY27.
2 more points from Gem Aromatics Ltd's call on order book
Create a free account to keep reading this call
Gem Aromatics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹110 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gem Aromatics Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate Ltd (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP Ltd (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals Ltd (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gem Aromatics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gem Aromatics Ltd Q4 FY26 results?
GEM Aromatics is focused on scaling high-value specialty products and improving utilization levels, especially at the Dahej facility. FY ‘27 guidance is cautious due to geopolitical uncertainties and raw material price volatility; detailed guidance expected in 1-2 quarters.
What is Gem Aromatics Ltd share price analysis?
Gem Aromatics Ltd currently shows a neutral. The stock trades at a P/E of 678.7 with a market cap of ₹964 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gem Aromatics Ltd planning capital expenditure?
Total planned capex for Dahej project is approximately INR 270 crores, with nearly INR 260 crores already incurred and substantially capitalized (Page 4).
Keep Gem Aromatics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.